Combination Chemotherapy Shows Promise in Patients with Blood Cancers

Patients with relapsed and/or chemotherapy refractory blood cancers responded to a combination regimen of the chemotherapy drugs thioguanine and decitabine during a phase 1 clinical trial.

For the trial, investigators tested the efficacy of the combination therapy in 12 older patients with relapsed or chemotherapy refractory acute myeloid leukemia (AML) or chronic myelomonocytic leukemia. This included 6 patients whose disease had progressed after being previously treated with decitabine monotherapy.

There were 11 patients who completed the first treatment cycle, and 6 who completed a second cycle, with a median of 3 treatment rounds.

The results of the study, presented at the American Society of Hematology’s annual conference, showed that 8 of 11 patients responded to the combination therapy, including 6 who achieved a complete remission (5 in complete remission with incomplete count recovery).

Additional findings revealed that all patients who progressed after prior treatment with decitabine alone responded to the combination treatment, indicating the ability of the combination to overcome decitabine resistance.

Chemosensitivity assay results obtained before the start of treatment accurately predicted each patient’s response to the combination therapy. After treatment, 4 of the responders went on to receive a stem cell transplant.

“The goal of chemotherapy for patients with relapsed and/or refractory AML and other blood cancers is to achieve a remission that enables them to undergo a potentially curative stem cell transplant,” said investigator Dr Mark Frattini, MD, PhD. “With our phase 1 results, we have shown that this combination therapy can get some patients ––including those who failed to respond to or progressed after previous chemotherapy treatment with a single agent such as decitabine–– to that point. The next challenge for hematologic oncologists is to reduce morbidity and mortality associated with stem cell transplantation.”

After the completion of the study, 2 of the patients who had a stem cell transplant died from transplant-related toxicity, and another relapsed, according to the study. However, 1 patient remained in remission for more than 2 years.

“Outcomes are typically poor for older patients with advanced blood cancers, and new therapies are desperately needed to help patients with these cancers achieve remission,” Frattini said. “While our study was small, the response we saw in this phase 1, dose-escalating trial was encouraging.”

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.
Top news of the day from across the health care landscape.
Photobiomodulation therapy found effective for the prevention of oral mucositis caused by radiation therapy.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.